{"nctId":"NCT01720069","briefTitle":"Clinical Study to Evaluate the Efficacy and Safety of VR506 Using a New Inhaler for the Treatment of Asthma","startDateStruct":{"date":"2012-10"},"conditions":["Asthma"],"count":197,"armGroups":[{"label":"Dose 1 VR506","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: VR506"]},{"label":"Dose 2 VR506","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: VR506"]},{"label":"Dose 3 VR506","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: VR506"]}],"interventions":[{"name":"VR506","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion:\n\n* Written informed consent\n* Adolescents aged 12-17 years \\& adults aged 18-65 years (both inclusive)\n* Documented clinical history of severe asthma requiring prednisone/prednisolone therapy, high-intensity treatment ICS, OCS, LABA\n* Stable OCS dose for ≥7 days before Screening Visit \\& during Screening Period.\n* At least 80% compliant w/regular asthma medication per investigator at end of Screening Period\n* Documented asthma reversibility within 5 yrs prior to/during Screening Period, or diagnosis of asthma that is incontrovertible per investigator\n* Ability to use nDPI correctly, per investigator's review of completed inhaler operation checklist\n* Ability to use eDiary correctly, assessed by investigator at end of Screening Period\n* Ability to comply w/study procedures, including blood sampling\n* Ability to perform technically satisfactory pulmonary function tests\n* Available to complete all study visits before 12 noon\n* BMI of 16-26 kg/m2 in adolescents and 18-32 kg/m2 in adults\n* Oral PIF ≥40 L/min, using an appropriate device set to match resistance of inhaler\n* Good health, except for presence of asthma, per medical history/physical examination\n* Negative drug/alcohol/urine cotinine screen. Subjects must test negative for amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, cotinine, ethanol \\& opiates (unless given as prescription medicine)\n* Non-smokers or ex-smokers with a smoking history of less than 10 pack-yrs (e.g. \\<20 cigarettes per day for 10 years or \\<40 cigarettes per day for 5 years) \\& stopped smoking for at least 1 year prior to Screening Visit. Smoking will not be permitted throughout study\n* Female subjects of child-bearing potential must be using medically acceptable forms of contraception \\[abstinence, hormonal (oral/implant/transdermal/injection), in use for ≥3 consecutive months before first dose of study medication, double barrier (condom w/spermicide, or diaphragm w/spermicide), IUD, or vasectomised partner (≥6 months since vasectomy)\\].\n\nExclusion:\n\n* Regular use (≥3 times/wk) of topical steroids to treat dermatitis/rhinitis/allergic conjunctivitis, within 28 days of Screening Visit\n* Subjects who have/who have had, an upper/lower respiratory tract infection within 28 days of Screening Visit\n* Subjects w/\"brittle asthma\n* Subjects w/asthma that required admission to an ICU and/or ventilation within previous 12 months\n* Subjects whose comorbidities, per investigator's opinion, are major contributors to their respiratory symptoms (e.g. COPD, bronchiectasis, dysfunctional breathlessness, vocal cord dysfunction, gastro-oesophageal reflux)\n* Previously/currently diagnosed as having Churg-Strauss syndrome\n* Previously/currently diagnosed as having pulmonary eosinophilia\n* History of lung cancer\n* Subjects w/current diagnosis of HIV infection\n* Active chronic hepatitis B or C infection\n* Subjects who have clinically significant abnormality/finding from examination, tests, or history that may compromise subject safety, specifically any history of cardiac, renal or hepatic impairment\n* Subjects with an abnormal ECG\n* Persistent arterial hypotension, with average SBP readings of ≤95 mmHg\n* Persistent elevation of blood pressure, with average SBP readings of ≥160 mmHg or average DBP readings of ≥100 mmHg\n* Pregnant or lactating females\n* Participation in another clinical study in 28 days prior to Screening Visit\n* Evidence of clinically significant renal, hepatic, cardiac, pulmonary (apart from asthma) or metabolic dysfunction, e.g. diabetes mellitus, thyrotoxicosis, uncorrectable hypokalaemia, or predisposition to low levels of serum potassium\n* Current/history of drug/alcohol abuse/dependence per WHO criteria\n* Inability to communicate well w/investigator\n* Donation of ≥450 mL of blood/blood products within previous 3 months prior to screening\n* History of allergy/intolerance/contraindications to corticosteroids/lactose, or severe allergy to milk proteins\n* Consumption of alcohol- or caffeine-containing foods/beverages from midnight before or during Screening Visit\n* History of medically diagnosed chronic respiratory diseases other than asthma (e.g. chronic obstructive pulmonary disease, ABPA in the absence of asthma)","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"65 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Prednisone/Prednisolone Dose for Analysis (PDA) at End of Study (Week 16)","description":"The mean asthma control prednisone/prednisolone dose at end of study (week 16)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.55","spread":"6.85"},{"groupId":"OG001","value":"4.31","spread":"7.38"},{"groupId":"OG002","value":"3.97","spread":"6.21"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Start of Treatment Baseline to End of Study (Week 16) for In-clinic Morning Pre-Dose Forced Expiratory Volume In 1 Second (FEV1)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.4"},{"groupId":"OG001","value":"0.02","spread":"0.31"},{"groupId":"OG002","value":"0.06","spread":"0.35"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Start of Treatment Baseline to End of Study (Week 16) for Asthma Control Questionnaire (ACQ-5) Mean Total Score","description":"Change from baseline to end of study (week 16) in 5 item asthma control questionnaire (ACQ-5) mean total score (range 0 (better) to 6 (worse)). The mean total score is calculated as the mean for each subject at each visit of 5 questions, each scored from 0 (better) to 6 (worse).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.67","spread":"0.98"},{"groupId":"OG001","value":"-0.77","spread":"1.15"},{"groupId":"OG002","value":"-0.39","spread":"0.89"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Start of Treatment Baseline to End of Study (Week 16) for In-clinic Weekly Morning Pre-dose Peak Expiratory Flow (PEF)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":"45.7"},{"groupId":"OG001","value":"20.1","spread":"51.7"},{"groupId":"OG002","value":"6.1","spread":"53.5"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Start of Treatment Baseline to End of Study (Week 16) for Weekly Average Asthma Night-time Symptom Score","description":"To measure the change from baseline to end of study for the weekly mean asthma night time symptom score, scored from 0 (not at all bothered) to 6 (severely bothered).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"1"},{"groupId":"OG001","value":"-0.6","spread":"1"},{"groupId":"OG002","value":"-0.2","spread":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Withdrawals Due to Worsening of Asthma","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Assessment of Acceptability of the Device","description":"Percentage of subjects that overall found it very easy or fairly easy to use the inhaler, based on inhaler acceptability questionnaire","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"49","spread":null},{"groupId":"OG002","value":"38","spread":null}]},{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"21","spread":null},{"groupId":"OG002","value":"21","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":62},"commonTop":["Asthma","Headache","Oropharyngeal pain","Respiratory tract infection","Acute sinusitis"]}}}